TransMedics Group Inc (TMDX)
137.97
+3.04
(+2.25%)
USD |
NASDAQ |
May 17, 16:00
139.51
+1.54
(+1.12%)
Pre-Market: 20:00
TransMedics Group Research and Development Expense (Quarterly): 11.38M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 11.38M |
December 31, 2023 | 10.76M |
September 30, 2023 | 38.34M |
June 30, 2023 | 8.291M |
March 31, 2023 | 5.871M |
December 31, 2022 | 5.756M |
September 30, 2022 | 6.808M |
June 30, 2022 | 6.714M |
March 31, 2022 | 7.534M |
December 31, 2021 | 6.314M |
September 30, 2021 | 5.163M |
June 30, 2021 | 6.295M |
March 31, 2021 | 4.532M |
Date | Value |
---|---|
December 31, 2020 | 4.548M |
September 30, 2020 | 4.155M |
June 30, 2020 | 3.903M |
March 31, 2020 | 6.225M |
December 31, 2019 | 6.262M |
September 30, 2019 | 4.939M |
June 30, 2019 | 4.787M |
March 31, 2019 | 3.882M |
December 31, 2018 | 3.486M |
September 30, 2018 | 3.272M |
June 30, 2018 | 3.433M |
March 31, 2018 | 3.465M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.903M
Minimum
Jun 2020
38.34M
Maximum
Sep 2023
7.929M
Average
6.244M
Median
Research and Development Expense (Quarterly) Benchmarks
SI-BONE Inc | 4.345M |
Cutera Inc | 5.001M |
Stereotaxis Inc | 2.243M |
Electromed Inc | 0.167M |
Myomo Inc | 0.9562M |